Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Thomas H. Schroeder

Essen, NW, DE 
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Thomas Schroeder practices in Essen, Germany. Mr. Schroeder is rated as an Experienced expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 191 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Gender
Male

Locations

Essen, NW, Germany
Other Locations
Duesseldorf, NW, Germany
Berlin, BE 12489, Germany
Cottbus, BB 03046, Germany
Leipzig, SN 04103, Germany
Heine, NW, Germany
Frankfurt Am Main, HE 15236, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug, Procedure
Study Drug: Ruxolitinib continuous therapy
Study Phase: Phase 2
Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)
Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, ATG
Study Phase: Phase 3
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

191 Total Publications

Treosulfan-based conditioning ameliorates impact of pretransplant MRD-positivity in AML patients allografted in remission.
Treosulfan-based conditioning ameliorates impact of pretransplant MRD-positivity in AML patients allografted in remission.
Journal: Transplantation and cellular therapy
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schroeder's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile